Results from Harvest One Cannabis’ (Harvest One Cannabis Stock Quote, Chart TSXV:HVT) third quarter were enough for analyst Greg McLeish of Mackie Research to maintain his bullish stance on the stock.
In a Friday update to clients, McLeish reiterated his “Buy” recommendation and $2.00 target for HVT, representing a projected return of 198.5 per cent at the time of publication.
Vancouver-based Harvest One released its Q3 fiscal 2019 financials on May 30, achieving net revenue of $3.0 million and $8.4 million for the three and nine months ended March 31, 2019.
“During the third quarter, we achieved increasing harvests as we continue to enhance existing facilities and build out new capacity. In preparation for the roll out of value-added products later this year, we also allocated a portion of our inventory accordingly for extraction and future R&D. The impact of these value-added products will be reflected in the financial results in future quarters,” said CEO Grant Froese.
McLeish says HVT has all the pieces finally in place and that it’s now time to execute.
“Revenue for the quarter was $3.0 million versus our $3.9 million estimate. During the quarter the company streamlined its distribution network for its Dream Water subsidiary which negatively impacted revenue. This was the primary reason for the revenue miss,”
“Net loss for the quarter was $5.1 million or $0.03 per share compared to our net loss forecast of $4.7 million ($0.03 per share). The earnings miss was primarily attributable to acquisition and severance/reorganization expenses,” McLeish writes.
“At the end of Q3/19 the company had net cash of $29.5 million. This strong cash position will allow the company to build out 20,000 kg of production capacity, strategically increase its domestic geographic presence and address potential working capital requirements,” McLeish said.
The analyst noted that Harvest One’s horticultural arm, United Greeneries continues to target for 20,000 kg of production capacity, while fiscal 2019 should be a break-out year for Satipharm, HVT’s medical and nutraceutical arm, which experienced its share of regulatory hurdles which limited its ability to distribute product in the EU and resulted in significantly reduced sales.
“We believe that the majority of these issues are now behind the company and that it is on track for material revenue growth in fiscal 2020,” he says.